Drug Profile
Research programme: albumin and antibody drug conjugates - LadRx Corporation
Alternative Names: AE-Ester-Sulf07; AE-Keto-Sulf07; DK 049; FN296; LADR-10; LADR-7; LADR-8; LADR-9; PP072Latest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator Centurion BioPharma
- Developer LadRx Corporation
- Class Antineoplastics; Auristatins; Biological toxins; Drug conjugates; Maytansinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Albumin and antibody drug conjugates are still in preclinical trials for Cancer in USA
- 05 Apr 2024 LadRx Corporation has patent protection for LADRTM-related technology in USA and rest of the World
- 05 Apr 2024 LadRx Corporation has patents pending for LADRTM-related technology in USA and rest of the World